This dominance reflects the current treatment paradigm where GLP-1 medications are primarily positioned and reimbursed for obesity management based on BMI criteria rather than cardiovascular risk reduction
doi: 10.1089/ars.2014.6200 49 MurphyMP
10.1073/pnas.90.17.7915 29
Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, Durkalski V, Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Smith A, Brown R, Crippin J, Harrison ME, Koch D, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hassanein T, Hanje AJ, Olson J, Subramanian R, Karvellas C, Hameed B, Sherker AH, Robuck P, Lee WM
They want a reliable resource without additional costs or subscriptions
The GLORY-2 trial tested the higher 9 mg dose